# Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

> **NCT02777229** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 616 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir 50 mg
- **DRUG:** Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
- **DRUG:** Efavirenz 400 mg

## Key facts

- **NCT ID:** NCT02777229
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-07
- **Final completion:** 2021-07
- **Target enrollment:** 616 (ACTUAL)
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777229, "Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02777229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*